AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04729296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive Drug
Trial: NCT04990219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - capsule
Trial: NCT05061524
Drug: YH35324
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of YH35324
Trial: NCT05061524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of None of active ingredient
Trial: NCT05230472
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 60 mg tab
Trial: NCT04771273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04758897
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
Trial: NCT05128305
Drug: traditional Chinese medicine1 and traditional Chinese medicine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We use two traditional Chinese medicine prescriptions to intervene in patients after TIPS
Trial: NCT06141577
Drug: UIC202201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take UIC202201 1cap/day for 7 days
Trial: NCT05268198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05376189
Drug: Fixed Drug Combination
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Tuberculosis Regimen in a form of Fixed Drug Combination (FDC) given for Spondylitis Tuberculosis.
Trial: NCT05566028
Drug: D745 formulation I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Trial: NCT05566028
Drug: D745 formulation II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Trial: NCT05566028
Drug: D745 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD for 24 weeks or 52 weeks(if extension study) with D150 and D759
Trial: NCT06492356
Drug: medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty patients will receive medical treatment by dermatologist.
Trial: NCT05541757
Drug: In vitro heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro heparin and in vitro LMWH
Trial: NCT06225804
Drug: ABSK112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the escalation part, patients will receive a single dose of oral ABSK112 on Cycle1 Day1 only, and then patients will continuously receive ABSK112 once daily (QD) or twice daily (BID) in subsequent cycles. In the expansion part, patients will each be treated at the selected RDE dose level.
Trial: NCT05406440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8189 dose-matching placebo tablets will be administered orally QD.
Trial: NCT06117904
Drug: Symptomatic treatment only
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets).
Trial: NCT05481333
Drug: REGN7999
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending IV or SC dose administered per protocol
Trial: NCT04858425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo tablets 400 mg 3 times daily for 14 days
Trial: NCT05031806
Drug: iNexin™ (0.08% aCT1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
Trial: NCT05031806
Drug: iNexin™ (0.4% aCT1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
Trial: NCT04926246
Drug: R1: Reference Product X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T1: Test Product M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T2: Test Product N
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T3: Test Product O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T4: Test Product O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fed conditions
Trial: NCT04926246
Drug: R2: Reference Product Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T5: Test Product P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T6: Test Product P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fed conditions
Trial: NCT04926246
Drug: T7: Test Product Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: R3: Reference Product Z
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T8: Test Product S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT04926246
Drug: T9: Test Product S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fed conditions
Trial: NCT04926246
Drug: T10: Test Product U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: under fasted conditions
Trial: NCT05235542
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral,Specified dose on specified days
Trial: NCT04888585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT04927975
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04700007
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.
Trial: NCT05759897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05479240
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Capecitabine, 1000mg/m2, day 1-14 of every 3 weeks for 6 cycles
Trial: NCT05528328
Drug: Placebo (saline solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution) administered in identic al vials
Trial: NCT05969236
Drug: MDI-1228_mesylate Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI-1228_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)
Trial: NCT05969236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228_mesylate is absent.
Trial: NCT04756804
Drug: 70% v/v Isopropyl Alcohol Surgical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preoperative skin preparation
Trial: NCT04756804
Drug: 2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preoperative skin preparation
Trial: NCT00002357
Drug: HBY 097
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05935332
Drug: RPT193
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Trial: NCT06141447
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL bag of normal saline alone
Trial: NCT05729932
Drug: Intransal opioid
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind opioid and placebo doses, administered intranasal route
Trial: NCT05923008
Drug: IBI130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Trial: NCT05195541
Drug: CU-20401
RxNorm normalized name: Cu 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection in the subcutaneous fat area，0.2ml
Trial: NCT05012644
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor
Trial: NCT05159518
Drug: PRT2527
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT2527 will be administered by intravenous infusion
Trial: NCT02245945
Drug: TFV 1% vaginal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
Trial: NCT02245945
Drug: HEC Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
Trial: NCT01353482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
Trial: NCT05039723
Drug: Radiesse, Xeomin, Belotero
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rejuvenation with Radiesse, Xeomin, Belotero
Trial: NCT06421948
Drug: cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
Trial: NCT04588285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
Trial: NCT06471218
Drug: SHR-1918; SHR-1918 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1918/SHR-1918 Placebo,two administration
Trial: NCT05083949
Drug: Glifage®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glifage® 850mg (R2)
Trial: NCT05391048
Drug: IMP4297(20mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
Trial: NCT05391048
Drug: IMP4297(10mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
Trial: NCT05481970
Drug: fentanyl,propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
Trial: NCT04890470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo
Trial: NCT05599971
Drug: intralesional injection of 5- Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 patients will receive intralesional injection of 5- Fluorouracil (50mg/ml) in full concentration into the wart using a 27- gauge insulin syringe till the entire lesion begins to puff up. The maximum dose injected per session will be 2ml of 5-FU. Selected patients will receive one session every 2 weeks till complete clearance or up to 5 sessions.
Trial: NCT06228443
Drug: ARAVA® 20 mg Film-coated Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARAVA® 20 mg Tablets (Reference Drug)
Trial: NCT06630208
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take pharmacological treatment prescribed by the cardiologist.
Trial: NCT05605704
Drug: atherolive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Trial: NCT04859426
Drug: DBPR108 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: DBPR108, tablet, oral
Trial: NCT05878535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets. Prescribed: Once daily PO with meals and 200 mL of water.
Trial: NCT05225857
Drug: AGA2118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 - SAD study: SAD participants in various cohorts will receive various single dose of AGA2118 via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive various multiple doses of AGA2118 Q4W via SC.
Trial: NCT05225857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 - SAD study: SAD participants in various cohorts will receive a single dose of placebo via either SC or IV.~Part 2 - MAD study: MAD participants in various cohorts will receive multiple doses of placebo via SC.
Trial: NCT06249633
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide
Trial: NCT06553287
Drug: LNK01004 ointment 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNK01004 ointment 0.3% for topical application
Trial: NCT06553287
Drug: LNK01004 ointment 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNK01004 ointment 1.0% for topical application
Trial: NCT06553287
Drug: LNK01004 ointment 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNK01004 ointment 1.5% for topical application
Trial: NCT05691660
Drug: TAS3731 Dose1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration,1 day,QD
Trial: NCT05691660
Drug: TAS3731 Dose2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration,7 days,QD
Trial: NCT05691660
Drug: TAS3731 Dose3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration,7 days,BID
Trial: NCT05691660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 1 day,QD
Trial: NCT05691660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 7 days,QD
Trial: NCT05691660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, 7 days,BID
Trial: NCT06555471
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 Bid po d1-14，q3w，Reduce or discontinue depending on the condition of the subject.
Trial: NCT05043987
Drug: CPO102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-claudin 18.2 Antibody-MMAE Drug Conjugate
Trial: NCT06174116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take placebo for 12 weeks, in addition to their regular medications.
Trial: NCT04731922
Drug: TAK-510 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-510 placebo-matching solution.
Trial: NCT05027867
Drug: KRT-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by mouth
Trial: NCT04173390
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
Trial: NCT06086457
Drug: TP or PF regimen depended on investigator's choice.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A maximum of six cycles was recommended for chemotherapy. Chemotherapy Regimen 1(TP regimen A): Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W； Chemotherapy Regimen 2 (TP regimen B): Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W； PD-1 inhibitor 200mg, d1, Q3W Chemotherapy Regimen 3 (PF regimen): Capecitabine 800mg/m2, bid, d1-14; Cisplatin 25-30mg/m2, d1,d2, Q3W.
Trial: NCT01108913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05798819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06514001
Drug: AMDX-2011P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Trial: NCT03570814
Drug: Administration of Azithromycin on Day 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
Trial: NCT03570814
Drug: Administration of Azithromycin on Day 15
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
Trial: NCT04940676
Drug: Huzhangxiefei Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
Trial: NCT04940676
Drug: 10% Huzhangxiefei Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Huzhangxiefei Decoction, 50ml, Oral Administered or Nasal Feeding 5 minutes after breakfast and dinner for 7 days
Trial: NCT05069935
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning agent
Trial: NCT04950530
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet
RxNorm normalized name: Biktarvy 50mg-200mg-25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide taken once daily, orally
Trial: NCT05330208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05170763
Drug: PA9159 nasal spray solution, 10 μg one day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, one spray each in the left and right nostril.
Trial: NCT05170763
Drug: PA9159 nasal spray solution, 20 μg one day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PA9159 (5 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Trial: NCT05170763
Drug: PA9159 nasal spray solution, 40 μg one day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Trial: NCT05170763
Drug: PA9159 nasal spray solution, 80 μg one day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, four sprays each in the left and right nostril.
Trial: NCT05170763
Drug: PA9159 nasal spray solution, 20 μg 7-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of PA9159 (5 μg/nasal spray) or Placebo is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Trial: NCT05170763
Drug: PA9159 nasal spray solution, 40 μg 7-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of PA9159 (10 μg/nasal spray) is delivered intranasally through a metered-dose mechanical spray pump, two sprays each in the left and right nostril.
Trial: NCT05170763
Drug: Placebo, the same intranasal spray solution without PA9159 active ingredient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is delivered intranasally through a metered-dose mechanical spray pump with the same volume as the corresponding PA9159 dose group
Trial: NCT06029049
Drug: RSI succinylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC